申请人:——
公开号:US20030166724A1
公开(公告)日:2003-09-04
New thyroid receptor ligands are provided which have the general formula I
1
wherein
R
1
is halogen, trifluoromethyl, substituted or unsubstituted aryl, substituted or unsubstituted C
1-6
alkyl, or substituted or unsubstituted C
3-7
cycloalkyl;
R
2
and R
3
are each independently hydrogen, halogen, substituted or unsubstituted C
1-4
alkyl, or substituted or unsubstituted C
3-6
cycloalkyl, wherein at least one of R
2
and R
3
is other than hydrogen;
R
4
is a carboxylic acid selected from the group consisting of (CH
2
)
n
COOH, (CH)
2
COOH, NHCO(CH
2
)
n
COOH, CONH(CH
2
)
n
COOH and NH(CH
2
)
m
COOH;
n is an integer from 0 to 4; and
m is an integer from 1 to 4.
In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T
3
regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
提供了具有通式 I 的新型甲状腺受体配体
1
其中
R
1
是卤素、三氟甲基、取代或未取代的芳基、取代或未取代的 C
1-6
烷基,或取代或未取代的 C
3-7
环烷基;
R
2
和 R
3
各自独立地为氢、卤素、取代或未取代的 C
1-4
烷基,或取代或未取代的 C
3-6
环烷基,其中至少一个 R
2
和 R
3
不是氢;
R
4
是一种羧酸,选自由(CH
2
)
n
COOH、(CH)
2
COOH、NHCO(CH
2
)
n
COOH、CONH(CH
2
)
n
COOH 和 NH(CH
2
)
m
COOH;
n 是 0 至 4 的整数;和
m 是 1 至 4 的整数。
此外,还提供了一种方法,用于预防、抑制或治疗与代谢功能障碍有关的疾病或依赖于 T
3
调节基因表达的疾病的方法,其中上述化合物以治疗有效量给药。